Which biologic treatment was the first to receive FDA approval for patients with uncontrolled COPD?

Dupilimab received FDA approval as the first biologic treatment for adults with uncontrolled COPD, reducing exacerbations significantly in clinical trials. A study in JAMA Internal Medicine demonstrated that improper arm positioning during blood pressure measurements can lead to overestimated readings, potentially causing misdiagnosis. Another study in Atherosclerosis, Thrombosis, and Vascular Biology linked COVID-19 to long-term risks of major adverse cardiac events (MACE), with increased risks for patients hospitalized with COVID-19 and those with non-O blood types. These findings underscore the need for attention to proper clinical practices and long-term monitoring of cardiovascular health post-COVID-19.